tiprankstipranks
Advertisement
Advertisement
Video: AeroVironment jumps after Q4 earnings beat
PremiumThe FlyVideo: AeroVironment jumps after Q4 earnings beat
21d ago
Replimune price target raised to $9 from $6 at Wedbush
Premium
The Fly
Replimune price target raised to $9 from $6 at Wedbush
21d ago
BMO double upgrades Replimune on higher chances of FDA approval
Premium
The Fly
BMO double upgrades Replimune on higher chances of FDA approval
21d ago
Replimune announces FDA acceptance of RP1 biologics license application
PremiumThe FlyReplimune announces FDA acceptance of RP1 biologics license application
25d ago
Regenxbio tells WSJ that FDA will reverse rejection of drug
Premium
The Fly
Regenxbio tells WSJ that FDA will reverse rejection of drug
29d ago
Acting FDA head vows to block political interference, Endpoint News says
Premium
The Fly
Acting FDA head vows to block political interference, Endpoint News says
2M ago
Replimune presents final first-in-human data for RP2 alone, with nivolumab
PremiumThe FlyReplimune presents final first-in-human data for RP2 alone, with nivolumab
2M ago
Replimune presents 3-year overall survival data from IGNYTE trial
Premium
The Fly
Replimune presents 3-year overall survival data from IGNYTE trial
2M ago
Replimune upgraded to Neutral at JPMorgan with RP1 ‘back on the table’
Premium
The Fly
Replimune upgraded to Neutral at JPMorgan with RP1 ‘back on the table’
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100